Journal of Oncology / 2020 / Article / Tab 2

Research Article

Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 2

Chemotherapy regimens that were administered as first-line treatment.

First-line chemotherapy regimenN%

Nab-paclitaxel/gemcitabine11358.5
Gemcitabine168.3
Gemcitabine/5-fluorouracil10.5
Gemcitabine/oxaliplatin52.6
Gemcitabine/cisplatin31.6
Gemcitabine/carboplatin10.5
Gemcitabine/erlotinib10.5
Gemcitabine/temsirolimus10.5
FOLFIRINOX3618.7
CAPOXIRI63.1
FOLFOX42.1
CAPOX21.0
FOLFIRI10.5
CDDP/LV/5-fluorouracil21.0
Cisplatin/etoposide10.5
Total193100.0

CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capecitabine; CDDP, cisplatin; FOLFIRI, irinotecan/leucovorin/5-fluorouracil; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.